Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Nature 2020 ; 584 (7821): 437-442 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Convergent antibody responses to SARS-CoV-2 in convalescent individuals #MMPMID32555388
Robbiani DF; Gaebler C; Muecksch F; Lorenzi JCC; Wang Z; Cho A; Agudelo M; Barnes CO; Gazumyan A; Finkin S; Hagglof T; Oliveira TY; Viant C; Hurley A; Hoffmann HH; Millard KG; Kost RG; Cipolla M; Gordon K; Bianchini F; Chen ST; Ramos V; Patel R; Dizon J; Shimeliovich I; Mendoza P; Hartweger H; Nogueira L; Pack M; Horowitz J; Schmidt F; Weisblum Y; Michailidis E; Ashbrook AW; Waltari E; Pak JE; Huey-Tubman KE; Koranda N; Hoffman PR; West AP Jr; Rice CM; Hatziioannou T; Bjorkman PJ; Bieniasz PD; Caskey M; Nussenzweig MC
Nature 2020[Aug]; 584 (7821): 437-442 PMID32555388show ga
During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2(1-5). Here we report on 149 COVID-19-convalescent individuals. Plasma samples collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres; titres were less than 50 in 33% of samples, below 1,000 in 79% of samples and only 1% of samples had titres above 5,000. Antibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC(50) values) as low as 2 ng ml(-1). In conclusion, most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.